142 related articles for article (PubMed ID: 35557490)
1. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Chalayer E; Talbot A; Frenzel L; Karlin L; Collet P; Guyotat D; Attal M; Leleu X; Tardy B
J Thromb Haemost; 2022 Aug; 20(8):1859-1867. PubMed ID: 35557490
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis.
Costa BA; Costa TA; Saravia SD; Felix N; Tan CR; Korde N; Richter J
Am J Hematol; 2024 Jun; 99(6):1056-1065. PubMed ID: 38488702
[TBL] [Abstract][Full Text] [Related]
4. Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
Loncharich AJ; Fiala MA; Slade MJ; Vickroy A; Kavanaugh M; Wilson C; Schroeder MA; Stockerl-Goldstein K; Vij R; Sanfilippo KM
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):825-828. PubMed ID: 37543510
[TBL] [Abstract][Full Text] [Related]
5. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
Li Q; Zhang B; Cheng Q; Zhao F; Li J; Yan H; Xu A; Sun C; Hu Y
Ann Med; 2023; 55(2):2263019. PubMed ID: 37983471
[TBL] [Abstract][Full Text] [Related]
6. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N
Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516
[TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
8. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Carrier M; Le Gal G; Tay J; Wu C; Lee AY
J Thromb Haemost; 2011 Apr; 9(4):653-63. PubMed ID: 21255254
[TBL] [Abstract][Full Text] [Related]
9. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
11. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Frenzel L; Decaux O; Macro M; Belhadj-Merzoug K; Manier S; Touzeau C; Leleu X; Frère C; Lecompte T; Perrot A; Avet-Loiseau H; Moreau P; Chalayer E
Thromb Res; 2024 Jan; 233():153-164. PubMed ID: 38064842
[TBL] [Abstract][Full Text] [Related]
13. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
14. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
17. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Sborov DW; Baljevic M; Reeves B; Laubach J; Efebera YA; Rodriguez C; Costa LJ; Chari A; Silbermann R; Holstein SA; Anderson LD; Kaufman JL; Shah N; Pei H; Patel S; Cortoos A; Bartlett JB; Vermeulen J; Lin TS; Voorhees PM; Richardson PG
Br J Haematol; 2022 Nov; 199(3):355-365. PubMed ID: 36111391
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Baljevic M; Sborov DW; Lim MY; Hillengass J; Martin T; Castillo JJ; Streiff MB; Kumar SK; Callander NS
J Natl Compr Canc Netw; 2022 Jan; 20(1):91-95. PubMed ID: 34991076
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Roussel M; Hebraud B; Hulin C; Perrot A; Caillot D; Stoppa AM; Macro M; Escoffre M; Arnulf B; Belhadj K; Karlin L; Garderet L; Facon T; Guo S; Weng J; Dhanasiri S; Leleu X; Moreau P; Attal M
Leuk Lymphoma; 2020 Jun; 61(6):1323-1333. PubMed ID: 32090636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
